The three compounds are BL-1030, a small molecule for the treatment of inflammatory bowel disease, BL-1050, a novel HIV therapeutic, and BL-2010, an innovative technology for the treatment of resistant cancer. The worldwide exclusive license agreements were signed with Rimonyx Pharmaceuticals of Nes Ziona, Israel, for the development of BL-1030; Yissum, the technology transfer company of The Hebrew University in Jerusalem for BL-1050; Ramot at Tel Aviv University, the technology transfer company of Tel Aviv University, and Bar Ilan R&D Company (BIRAD), the technology transfer office of Bar Ilan University for the development of BL-2010. BioLineRx plans to develop these projects through its pre-clinical development unit, BioLine Innovations Jerusalem, and to submit the projects for funding by the Israeli office of the chief scientist under the national biotech grant that BioLineRx received in November 2004. BL-1030 is an L-selectin inhibitor that disrupts the early steps of inflammation, thereby reducing tissue damage. In chronic inflammatory disorders such as inflammatory bowel disease (IBD), an event that triggers inflammation causes a chain reaction that fuels the disease for long periods of time. BL-1030 represents a novel approach for treating IBD: it stops the inflammatory cycle by blocking L-selectin, which plays a key role in recruiting inflammatory cells to tissue. At present, IBD is treated with steroids and immunosuppressive drugs; however the drugs significant side effects limit their use for chronic diseases. BL-1050 is a novel compound that prevents an HIV-infected cell from producing copies of infectious viral particles. This reduces the number of HIV particles in the bloodstream, slowing the progression of disease in the patient. BL-2010 is a chemotherapeutic approach for treating tumors that are resistant to standard therapies, such as 5-fluorouracil (5-FU). BL-2010 reduces tumor growth in animal models with improved safety and efficacy over conventional drug therapy. It will be developed initially for treatment of drug-resistant colorectal and pancreatic tumors, and its use will then be expanded to cancers of the breast, lung, and prostate.